Press Releases
Cocrystal Pharma Announces Presentation of Preclinical Characterization Data of CC-42344 at the 6th ISIRV-AVG Conference
Cocrystal Pharma Reports 2018 Third Quarter Financial Results and Provides Corporate Update
Cocrystal Pharma Announces Clinical Trial Agreement for Investigator-Initiated Phase 2a Study in Hong Kong of CC-31244 for Ultra-Short Treatment of Hepatitis C Virus
Cocrystal Pharma Completes Patient Enrollment in Phase 2a Study Evaluating CC-31244 for Ultra-Short Treatment of Hepatitis C
Cocrystal Pharma Reports 2018 Second Quarter Financial Results and Provides Corporate Update
Cocrystal Pharma Commences Enrollment and Initiates Patient Dosing in Phase 2a Study Evaluating CC-31244 for the Treatment of HCV
Cocrystal Pharma Announces Inclusion in Russell Microcap® Index
Cocrystal Pharma Announces Nasdaq Closing Bell Ceremony
Cocrystal Pharma Reports 2018 First Quarter Financial Results and Provides Corporate Update
